HUTCHMED presents HMPL-A830 preclinical data for pan-KRAS cancer therapy
AI Summary- HUTCHMED presented preclinical data for HMPL-A830 at an international cancer research conference.
- 55 tumor cell lines showed activity across KRAS G12C, G12D, G12V and G13D alterations.
- HUTCHMED and a GSK subsidiary signed a September 2026 development and licensing agreement.